Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine, discusses indatuximab ravtansine (BT062) in combination with lenalidomide (Revlimid) in patients with relapsed or refractory multiple myeloma.
Kevin R. Kelly, MD, PhD
Advertisement
Articles by Kevin R. Kelly, MD, PhD
Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine discusses reolysin plus bortezomib (Velcade) in paitents with multiple myeloma.
Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine, discusses a study examining racial disparities in patients with multiple myeloma.
Advertisement
Latest Updated Articles
Dr. Kelly on Racial Disparities in Multiple MyelomaPublished: January 13th 2017 | Updated:
Dr. Kelly on Phase Ib Study of Reolysin Plus Bortezomib in Multiple MyelomaPublished: February 11th 2017 | Updated:
- Dr. Kelly on BT062 Combination With Lenalidomide for R/R Myeloma
Published: February 20th 2017 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Unpacking the FDA Approvals That Reshaped Cancer Care in 2025
2
Nogapendekin Alfa Inbakicept Plus NK Cell Therapy Yields Strong OS Signal in Recurrent Glioblastoma
3
Immune-Targeting Vaccine Shows Promise Intercepting Cancer in Patients With Lynch Syndrome
4
FDA Grants Orphan Drug Designation to Gotistobart in Squamous NSCLC
5